Business
ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline
New findings highlight that PMN310 was able to target toxic amyloid-beta oligomers more selectively than other amyloid-beta-directed antibodies which were
About this update from Promis Neurosciences Inc.
[{"type":"text","content":"New findings highlight that PMN310 was able to target toxic amyloid-beta oligomers more selectively than other amyloid-beta-directed antibodies which were generated using synthetic oligomersRationally designed vaccine candidate for prevention of Alzheimer’s disease showed robust and sustained antibody response focused on pathogenic amyloid-beta oligomers TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 17, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), presented preclinical data further supporting the potential therapeutic advantage of lead candidate for AD, PMN310, a humanized IgG1 antibody directed toward toxic amyloid-beta oligomers (AβO). Additionally, the Company presented preclinical mouse studies that further characterize a computationally-derived AD vaccine directed at AβO. ProMIS’s proprietary algorithm identifies targets specific to a toxic protein species to avoid cross-reactivity with other forms of the same protein. The data were presented in posters on July 16, 2023, at the Alzheimer’s Association International Conference (AAIC) 2023 in Amsterdam, Netherlands. “We are excited about the new data presented at the AAIC conference on mechanisms and monitoring of Alzheimer’s disease and emerging treatment options which we believe may improve the lives of patients and their families,” said Gail Farfel, Ph.D., Chief Executive Officer of ProMIS Neurosciences. “The increasingly recognized benefit of targeting oligomers of Aβ underscores the potential advantage of our PMN310 antibody and AβO vaccine candidates. Both were generated using our proprietary computational modeling platform to identify epitopes restricted to misfolded, toxic AbO thereby providing a highly selective AβO-targeted response for potentially greater clinical activity and improved safety profile compared to less selective approaches. Furthermore, we are far along in our preparations to move PMN310 into clinical development with an informative trial design to evaluate its potential as a treatment for Alzheimer’s disease.” In May 2023, ProMIS received clearance from th...